Sugi Predict

Sugi Predict / Compounds / SCHEMBL185757

SCHEMBL185757

SCHEMBL185757

NS(=O)(=O)c1cccc(CO)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 13/20 0.61
▸ CA1 P00915 11/20 0.61
▸ CA12 O43570 10/20 0.59
▸ CA9 Q16790 10/20 0.59
▸ CA14 Q9ULX7 6/20 0.59
▸ CA4 P22748 5/20 0.59
▸ CA5A P35218 5/20 0.59
▸ CA6 P23280 4/20 0.59
▸ CA7 P43166 4/20 0.59
▸ CA5B Q9Y2D0 4/20 0.59
▸ PTGES2 Q9H7Z7 1/20 0.50
▸ NOS1 P29475 1/20 0.47
▸ ENPP2 Q13822 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ CA3 P07451 1/20 0.46
▸ PLA2G7 Q13093 1/20 0.46
▸ CA13 Q8N1Q1 1/20 0.46
▸ MAPT P10636 1/20 0.45
▸ GLO1 Q04760 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6256281 0.93 CA2 (0.53) CA2CA1CA12CA9CA14
Biphenyl SCHEMBL2902198 0.91 PTGES2 (0.54) CA2CA1CA12CA9CA14
SCHEMBL6252199 0.88 CA1 (0.59) CA2CA1CA12CA9CA14
SCHEMBL8196817 0.85 CA2 (0.61) CA2CA1CA12CA9CA14
SCHEMBL5436203 0.82 CA2 (0.64) CA2CA1CA12CA9CA14
SCHEMBL1775181 0.82 CA2 (0.64) CA2CA1CA12CA9CA14
SCHEMBL10586812 0.82 TSHR (0.53) CA2CA1CA12CA9CA14
SCHEMBL1795003 0.82 CA2 (0.64) CA2CA1CA12CA9CA14
SCHEMBL3000368 0.81 CA1 (0.57) CA2CA1CA12CA9CA14
SCHEMBL7188667 0.80 PTGES2 (0.64) CA2CA1CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 — — US claimed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 — — US claimed
CN-109790122-B Heterocyclic compounds 武田药品工业株式会社 2022-06-24 — — CN claimed
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 — — US disclosed
EP-4626548-A1 NON PEPTIDERGIC AGONISTS OF OXYTOCIN RECEPTOR Université de Strasbourg (FR) 2025-10-08 — — EP disclosed
CN-119677727-A GCN2 modulator compounds 阿莱斯塔治疗公司 2025-03-21 — — CN disclosed
US-12186317-B2 Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase TES PHARMA S.R.L. (IT) 2025-01-07 — — US disclosed
US-20240409542-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2024-12-12 — — US disclosed
US-20240390371-A1 HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATING ACUTE INFLAMMATION TES PHARMA S.R.L. (IT) 2024-11-28 — — US disclosed
WO-2024240882-A1 HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR USE IN TREATING ACUTE INFLAMMATION TES PHARMA S.R.L. (IT) 2024-11-28 — — WO disclosed
EP-4408845-A1 NOVEL COMPOUNDS Sitryx Therapeutics Limited (GB) 2024-08-07 — — EP disclosed
US-20050256201-A1 Phenethanolamine derivatives GLAXO GROUP LIMITED 2005-11-17 — — US disclosed
WO-2005082890-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-09 — — WO disclosed
US-20050075394-A1 Phenethanolamine derivatives for treatment of respiratory diseases GLAXO GROUP LIMITED (GB) 2005-04-07 — — US disclosed
CN-1585633-A Phenylethanolamine derivatives for the treatment of respiratory diseases GLAXO GROUP LTD (GB) 2005-02-23 — — CN disclosed
EP-1497261-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2005-01-19 — — EP disclosed
EP-1425001-A1 PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES GLAXO GROUP LIMITED (GB) 2004-06-09 — — EP disclosed
WO-2003091204-A1 PHENETHANOLAMINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-11-06 — — WO disclosed
WO-2003024439-A1 PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-03-27 — — WO disclosed
EP-1020434-A1 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH Kissei Pharmaceutical Co., Ltd. (JP) 2000-07-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 CA2 1341/4885CA1 3553/4885CA12 4051/4885
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS EIF2AK4, GPR119, GCN1 CA2 2579/4885CA1 4675/4885CA12 4797/4885
US-12186317-B2 Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase ACMSD, GLS, ALDH7A1 CA2 1019/4885CA1 1786/4885CA12 2470/4885
US-20050256201-A1 Phenethanolamine derivatives PNMT, PHOSPHO1, NAPEPLD CA2 2017/4885CA1 4463/4885CA12 3325/4885
US-20050075394-A1 Phenethanolamine derivatives for treatment of respiratory diseases PHOSPHO1, PNMT, PEBP1 CA2 3533/4885CA1 4866/4885CA12 4150/4885
US-20240409542-A1 NOVEL COMPOUNDS CD47, GPR119, LRBA CA2 4305/4885CA1 4324/4885CA12 2812/4885
US-20240390371-A1 HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATING ACUTE INFLAMMATION NFKBIA, MPO, LITAF CA2 3276/4885CA1 3145/4885CA12 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.